Oppenheimer & Co. Inc. Has $414,000 Holdings in Moderna, Inc. (NASDAQ:MRNA)

Oppenheimer & Co. Inc. decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 73.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 9,964 shares of the company’s stock after selling 27,823 shares during the period. Oppenheimer & Co. Inc.’s holdings in Moderna were worth $414,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Intrinsic Value Partners LLC lifted its position in shares of Moderna by 91.1% in the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after purchasing an additional 24,505 shares in the last quarter. Banco Santander S.A. purchased a new stake in Moderna in the 3rd quarter worth approximately $3,550,000. John G Ullman & Associates Inc. boosted its stake in shares of Moderna by 341.3% during the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after buying an additional 38,400 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Moderna by 11.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after acquiring an additional 167,596 shares in the last quarter. Finally, abrdn plc increased its stake in shares of Moderna by 28.1% in the fourth quarter. abrdn plc now owns 315,912 shares of the company’s stock worth $12,842,000 after acquiring an additional 69,360 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Up 3.8 %

MRNA stock opened at $35.61 on Friday. The firm’s 50-day moving average price is $36.60 and its two-hundred day moving average price is $49.29. The stock has a market capitalization of $13.74 billion, a price-to-earnings ratio of -3.84 and a beta of 1.86. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MRNA. UBS Group cut their price target on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Evercore ISI set a $50.00 price objective on shares of Moderna in a research report on Friday, February 14th. Piper Sandler reissued an “overweight” rating and issued a $69.00 target price (down from $115.00) on shares of Moderna in a research report on Monday, November 18th. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and cut their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.